Swedish Orphan Biovitrum AB (publ) (B6E.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:15AM CEST. Market open.
| Previous close | 24.08 |
| Open | 24.08 |
| Bid | 24.10 x 76000 |
| Ask | 24.50 x 74000 |
| Day's range | 24.08 - 24.08 |
| 52-week range | 16.13 - 26.46 |
| Volume | |
| Avg. volume | 8 |
| Market cap | 8.231B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 44.59 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
All You Need to Know About Swedish Orphan Biovitrum (BIOVF) Rating Upgrade to Strong Buy
Swedish Orphan Biovitrum (BIOVF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Miss Estimates
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of -44.44% and 7.69%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Nurix Therapeutics, Inc. (NRIX) Soars 8.3%: Is Further Upside Left in the Stock?
Nurix Therapeutics, Inc. (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
© 2024 Yahoo. All rights reserved.